BIOCON · Healthcare · Biotechnology
Composite scorecard: 36/100 — Quality 45 · Valuation 2 · Growth 38 · Momentum 73
| Share price | ₹436.50 |
| Market cap | ₹63,122 Cr |
| P/E ratio | 80.0 |
| P/B ratio | 1.9 |
| ROE | 1.1% |
| ROCE | 6.2% |
| Dividend yield | 0.13% |
| Book value | ₹207.92 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹16,927 Cr | ₹369 Cr | 21.0% |
| 2025 | ₹15,262 Cr | ₹1,429 Cr | 21.0% |
| 2024 | ₹14,756 Cr | ₹1,298 Cr | 22.0% |
| 2023 | ₹11,174 Cr | ₹643 Cr | 22.0% |
| 2022 | ₹8,184 Cr | ₹772 Cr | 22.0% |
Biocon Limited, together with its subsidiaries, manufactures and sells biotechnology products and research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics, Biosimilars, and Research segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, multiple sclerosis, anti-fungal, anti-cancer, immunosuppressants, and specialty molecules; and biosimilars products consisting of pegfilgrastim, trastuzumab, bevacizumab, adalimumab, etanercept, ustekinumab, glargine, aspa